|Vigil® is a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer from which a surgical sample can be gathered.To date, we have conducted a Phase 1 study identifying the clinical dose and establishing the early safety profile for the platform. The tumor types studied in Phase 1 included, but not limited to:
When those cells are reintroduced back into the patient, these two modifications are designed to help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation. All together, the goal is to stimulate the existing components of the immune system with the intent to improve their antitumor responses. We simply enhance specific functions that assist in cancer antigen recognition and dampen other functions that cancer cells often employ to evade the immune system.
We believe our approach of exploiting the existing, highly-adapted immune system by presenting the entire neoantigen matrix and induced T-cell responses against their cancer has great promise.